Cyclopharm Limited (CYC) Stock Statistics & Valuation Metrics

Cyclopharm Limited has a market cap or net worth of AU$118.92M. The enterprise value is AU$104.41M.

Cyclopharm Limited has 111,136,850 shares outstanding. The number of shares has decreased by -2.65% in one year.

Cyclopharm Limited’s return on equity (ROE) is -0.31 and return on invested capital (ROIC) is -27.78%.

The current PE Ratio of Cyclopharm Limited is -12.39. Cyclopharm Limited’s PEG ratio is 0.26.

In the last 12 months, Cyclopharm Limited had revenue of 27.57M and earned -13.20M in profits. Earnings per share was -0.13.

In the last 12 months, operating cash flow was -12.57M and capital expenditures -880.76K, giving a free cash flow of -13.46M billion.

Cyclopharm Limited pays an annual dividend of AU$0.004, resulting in a dividend yield of ―

Cyclopharm Limited upcoming earnings date is Sep 2, 2025, TBA Not Confirmed.

Cyclopharm Limited as a current ratio of 3.99, with Debt / Equity ratio of 19.39%

In the past 12 months, Cyclopharm Limited has paid 126.17K in taxes.

Cyclopharm Limited EV to EBITDA ratio is -11.05, with an EV/FCF ratio of -11.17.

Cyclopharm Limited has AU$20.57M in cash and marketable securities with AU$8.29M in debt, giving a net cash position of -AU$12.28M billion.

Gross margin is 32.10%, with operating margin of -52.03%, and net profit margin of -47.87%.

The average price target for Cyclopharm Limited is AU$2.20, which is 11.43% higher than the current price. The consensus rating is Moderate Buy